PL2549995T3 - Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny - Google Patents
Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabinyInfo
- Publication number
- PL2549995T3 PL2549995T3 PL11714880T PL11714880T PL2549995T3 PL 2549995 T3 PL2549995 T3 PL 2549995T3 PL 11714880 T PL11714880 T PL 11714880T PL 11714880 T PL11714880 T PL 11714880T PL 2549995 T3 PL2549995 T3 PL 2549995T3
- Authority
- PL
- Poland
- Prior art keywords
- anatabine
- inflammation
- treatment
- synthesis methods
- synthesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/729,346 US8207346B2 (en) | 2010-03-23 | 2010-03-23 | Methods of synthesizing anatabine |
| US38381110P | 2010-09-17 | 2010-09-17 | |
| US38444710P | 2010-09-20 | 2010-09-20 | |
| US201161439473P | 2011-02-04 | 2011-02-04 | |
| US201161439483P | 2011-02-04 | 2011-02-04 | |
| EP11714880.9A EP2549995B1 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
| PCT/US2011/029613 WO2011119722A2 (en) | 2010-03-23 | 2011-03-23 | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2549995T3 true PL2549995T3 (pl) | 2021-09-27 |
Family
ID=44201080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11714880T PL2549995T3 (pl) | 2010-03-23 | 2011-03-23 | Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny |
| PL21165632.7T PL3871674T3 (pl) | 2010-03-23 | 2011-03-23 | Zastosowanie anatabiny do zmniejszania poziomów białka c-reaktywnego w surowicy krwi u osobnika |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21165632.7T PL3871674T3 (pl) | 2010-03-23 | 2011-03-23 | Zastosowanie anatabiny do zmniejszania poziomów białka c-reaktywnego w surowicy krwi u osobnika |
Country Status (8)
| Country | Link |
|---|---|
| EP (4) | EP3871674B1 (pl) |
| AU (5) | AU2011232478A1 (pl) |
| CA (1) | CA2794097C (pl) |
| DK (1) | DK2549995T3 (pl) |
| ES (1) | ES2869851T3 (pl) |
| PL (2) | PL2549995T3 (pl) |
| PT (1) | PT2549995T (pl) |
| WO (1) | WO2011119722A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1199733A1 (en) * | 2011-08-29 | 2015-07-17 | Philip Morris Products S.A. | Products for anti-inflammation support |
| EP2793026A1 (en) | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| CN113039180A (zh) * | 2018-12-17 | 2021-06-25 | 菲利普莫里斯生产公司 | 3-(1,2,3,6-四氢吡啶-2-基)吡啶戊二酸盐或其药学上可接受的溶剂化物 |
| EP4164595B1 (en) | 2020-06-15 | 2025-08-20 | Philip Morris Products S.A. | Anatabine powder compositions |
| KR20230061365A (ko) | 2020-09-03 | 2023-05-08 | 필립모리스 프로덕츠 에스.에이. | 분무 건조 저 흡습성 활성 분말 조성물 |
| PL4208152T3 (pl) | 2020-09-03 | 2025-09-22 | Philip Morris Products S.A. | Nisko higroskopijne aktywne kompozycje proszku |
| JP2023540191A (ja) | 2020-09-03 | 2023-09-22 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 凍結乾燥低吸湿性活性粉末組成物 |
| CN113880802A (zh) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法 |
| US20250043298A1 (en) | 2021-12-20 | 2025-02-06 | Philip Morris Products S.A. | Increasing anatabine in tobacco leaf by regulating methyl putrescine oxidase |
| CN115594662A (zh) * | 2022-10-19 | 2023-01-13 | 昆明理工大学（Cn） | 一种(s)-烟碱的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| DE4002784C1 (pl) | 1990-01-31 | 1991-04-18 | B.A.T. Cigarettenfabriken Gmbh, 2000 Hamburg, De | |
| US5065775A (en) | 1990-02-23 | 1991-11-19 | R. J. Reynolds Tobacco Company | Tobacco processing |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
| US6350479B1 (en) * | 1998-06-05 | 2002-02-26 | Regent Court Technologies | Treating depression with alcohol extracts of tobacco |
| US6764826B2 (en) * | 2000-06-08 | 2004-07-20 | Board Of Regents, The University Of Texas System | Inhibitors of C-reactive protein induced inflammation |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| CA2500739A1 (en) | 2002-10-09 | 2004-04-22 | Dmi Biosciences, Inc. | Diagnosis and monitoring of inflammation, ischemia and appendicitis |
| EP1809759B1 (en) | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
| CA2652773A1 (en) * | 2006-05-22 | 2007-12-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels |
| US8841329B2 (en) * | 2008-09-11 | 2014-09-23 | Dignity Health | Nicotinic attenuation of CNS inflammation and autoimmunity |
| US8151804B2 (en) | 2008-12-23 | 2012-04-10 | Williams Jonnie R | Tobacco curing method |
-
2011
- 2011-03-23 PL PL11714880T patent/PL2549995T3/pl unknown
- 2011-03-23 EP EP21165632.7A patent/EP3871674B1/en active Active
- 2011-03-23 WO PCT/US2011/029613 patent/WO2011119722A2/en not_active Ceased
- 2011-03-23 EP EP19162452.7A patent/EP3524245A1/en not_active Withdrawn
- 2011-03-23 EP EP19162458.4A patent/EP3524246A1/en not_active Withdrawn
- 2011-03-23 ES ES11714880T patent/ES2869851T3/es active Active
- 2011-03-23 EP EP11714880.9A patent/EP2549995B1/en active Active
- 2011-03-23 CA CA2794097A patent/CA2794097C/en active Active
- 2011-03-23 PL PL21165632.7T patent/PL3871674T3/pl unknown
- 2011-03-23 AU AU2011232478A patent/AU2011232478A1/en not_active Abandoned
- 2011-03-23 PT PT117148809T patent/PT2549995T/pt unknown
- 2011-03-23 DK DK11714880.9T patent/DK2549995T3/da active
-
2017
- 2017-03-08 AU AU2017201593A patent/AU2017201593C1/en active Active
-
2019
- 2019-01-08 AU AU2019200102A patent/AU2019200102B2/en active Active
- 2019-01-08 AU AU2019200103A patent/AU2019200103B2/en active Active
-
2020
- 2020-10-21 AU AU2020257090A patent/AU2020257090B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3871674B1 (en) | 2024-12-25 |
| EP3524246A1 (en) | 2019-08-14 |
| EP3871674A1 (en) | 2021-09-01 |
| CA2794097C (en) | 2016-08-09 |
| WO2011119722A3 (en) | 2011-12-29 |
| AU2019200103B2 (en) | 2020-07-30 |
| AU2017201593C1 (en) | 2019-06-27 |
| AU2019200103A1 (en) | 2019-01-31 |
| AU2020257090B2 (en) | 2021-12-02 |
| AU2017201593B2 (en) | 2019-02-28 |
| AU2019200102B2 (en) | 2020-07-30 |
| EP2549995B1 (en) | 2021-04-21 |
| CA2794097A1 (en) | 2011-09-29 |
| AU2017201593A1 (en) | 2017-03-30 |
| PT2549995T (pt) | 2021-07-29 |
| AU2019200102A1 (en) | 2019-01-31 |
| ES2869851T3 (es) | 2021-10-26 |
| DK2549995T3 (da) | 2021-05-25 |
| AU2011232478A1 (en) | 2015-11-19 |
| PL3871674T3 (pl) | 2025-04-14 |
| EP3524245A1 (en) | 2019-08-14 |
| EP2549995A2 (en) | 2013-01-30 |
| EP3871674C0 (en) | 2024-12-25 |
| AU2020257090A1 (en) | 2020-11-19 |
| WO2011119722A2 (en) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2549995T3 (pl) | Zastosowanie anatabiny w leczeniu stanów zapalnych i metody syntezy anatabiny | |
| PL2544682T3 (pl) | Fitokannabinoidy w leczeniu glejaka | |
| IL223241A0 (en) | Cysteamine derivatives and their use in the treatment of nash | |
| PL2714006T3 (pl) | Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu | |
| PL2252283T3 (pl) | Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby | |
| PL3199024T3 (pl) | Zastosowanie kompozycji cyklodekstryny i stosowne sposoby | |
| IL232256A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| SMT201600430B (it) | Inibitori di chinasi e loro uso nel trattamento del cancro | |
| HRP20160551T8 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| SI3552619T1 (sl) | Polipeptidi faktorja IX in načini njihove uporabe | |
| PL2523678T3 (pl) | Antagoniści Wnt i sposoby leczenia | |
| PL3489261T3 (pl) | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu | |
| PL2552959T3 (pl) | Przeciwciała przeciwko MUC16 i metody stosowania | |
| IL226049A0 (en) | Composition for use in the prevention and/or treatment of skin conditions and skin diseases | |
| PL2606120T4 (pl) | Ludzkie komórki ułatwiające tolerancję i ich zastosowanie | |
| PL2543357T3 (pl) | Kompozycja do zastosowania w leczeniu i zapobieganiu zaburzeniom związanym ze stanem zapalnym | |
| PL2830654T3 (pl) | Sposoby i kompozycje do leczenia zapalenia | |
| PT3004108T (pt) | Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças | |
| HRP20171280T1 (hr) | Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji | |
| PL3085786T3 (pl) | Zastosowanie aptamerów w terapii i/lub diagnostyce chorób autoimmunologicznych | |
| EP2574172A4 (en) | MATERIALS AND METHOD FOR TREATING INFLAMMATION | |
| HRP20170225T1 (hr) | Fosfoplatini i njihova uporaba za liječenje karcinoma | |
| IL229381B (en) | Brilacitidine and its results for use in the treatment of mucositis | |
| DK2536748T3 (da) | Neuregulin-antagonister og anvendelse deraf ved behandling af kræft | |
| EP2651894A4 (en) | THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT |